Core Viewpoint - The company is preparing for the production of injectable bortezomib, which has not yet been officially launched in the market [1] Group 1: Company Response - The company addressed investor concerns regarding the impact of the original drug (bortezomib) from Johnson & Johnson/Takeda on its operations [1] - The company indicated that injectable bortezomib is currently in the pre-production stage [1] Group 2: Market Position - The company was asked about the market share of other generic drug companies in the local market [1] - The company provided no specific details on its market share in the Australian market [1]

Core Points - The company has received marketing authorization for injectable bortezomib from the Australian Therapeutic Goods Administration (TGA) [1][4] - The product is indicated for multiple myeloma and mantle cell lymphoma treatment in specific patient populations [2][3] Drug Information - Product Name: Injectable Bortezomib - Dosage Form: Injection - Specification: 3.5 mg - Approved Indications: - Treatment of previously untreated multiple myeloma patients who are not suitable for high-dose chemotherapy, in combination with melphalan and prednisone [1] - Part of combination therapy for previously untreated multiple myeloma patients under 65 years old, for high-dose chemotherapy with autologous stem cell rescue [1] - Treatment for multiple myeloma patients who have received at least one prior therapy and have disease progression [2] - Treatment for adult patients with previously untreated mantle cell lymphoma in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone [2] Impact on the Company - The approval signifies the product's eligibility for sale in Australia, positively impacting the company's overseas market expansion and performance [4] - The export business may face uncertainties due to market demand fluctuations, policy changes, exchange rate volatility, and market competition [4]

Core Viewpoint - *ST Shuangcheng has received marketing approval from the Australian Therapeutic Goods Administration (TGA) for injectable bortezomib, indicating a significant advancement in its product portfolio and potential market opportunities in treating multiple myeloma and mantle cell lymphoma patients [1] Summary by Categories Product Approval - The company has obtained a marketing license for injectable bortezomib from the TGA [1] - The approved indications include treatment for previously untreated multiple myeloma patients who are unsuitable for high-dose chemotherapy, as well as those who have received at least one prior treatment and have disease progression [1] Treatment Combinations - Bortezomib is approved for use in combination with melphalan and prednisone for treating previously untreated multiple myeloma patients [1] - It is also indicated for use in conjunction with high-dose chemotherapy and autologous stem cell rescue for patients under 65 years old who have not received prior treatment [1] - Additionally, it is approved for use with rituximab, cyclophosphamide, doxorubicin, and prednisone for treating adult patients with previously untreated mantle cell lymphoma [1]

Core Viewpoint - *ST Shuangcheng (002693.SZ) has received marketing approval from the Australian Therapeutic Goods Administration (TGA) for injectable bortezomib, indicating a significant advancement in its product offerings for treating multiple myeloma and mantle cell lymphoma patients [1] Group 1: Product Approval Details - The approved indications for bortezomib include treatment for previously untreated multiple myeloma patients who are unsuitable for high-dose chemotherapy when used in combination with melphalan and prednisone [1] - It is also approved for use in patients under 65 years old with previously untreated multiple myeloma as part of a high-dose chemotherapy regimen combined with autologous stem cell rescue following prior induction therapy [1] - The drug is indicated for patients who have received at least one prior treatment and whose disease has progressed [1] - Additionally, it is approved for adult patients with previously untreated mantle cell lymphoma when used in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone [1]

上市许可的公告 证券代码：002693 证券简称：*ST双成 公告编号：2025-065 海南双成药业股份有限公司 关于注射用硼替佐米获得澳大利亚药物管理局（TGA） 3、规格：3.5mg 4、获批适应症： 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 海南双成药业股份有限公司（以下简称"公司"） 于近日收到澳大利亚药 物管理局（TGA）签发的注射用硼替佐米的上市许可，现将相关情况公告如下： 一、药品基本情况 1、药品商品名：注射用硼替佐米 2、剂型：注射剂 （1）与美法仑和泼尼松联合使用，适用于治疗既往未接受过治疗且不适合 接受大剂量化疗的多发性骨髓瘤患者。 （2）作为联合治疗的一部分，适用于 65 岁以下既往未接受过治疗的多发性 骨髓瘤患者，用于高剂量化疗联合自体干细胞挽救之前的诱导治疗。 （3）适用于至少接受过一次既往治疗且疾病进一步发展的多发性骨髓瘤患 者。 （4）与利妥昔单抗、环磷酰胺、多柔比星和泼尼松联合使用，适用于既往 未接受过治疗的套细胞淋巴瘤成人患者的治疗。 签发的《药品注册证书》，该产品获批视同其通过一致性评价。具体内容详见 2024 年 ...

Core Viewpoint - The article discusses the journey of small investors in the A-share market, highlighting the different phases of market behavior and strategies for maximizing returns, particularly during bull markets and the emergence of "hot stocks" [5][7]. Group 1: Market Phases - The investment journey is divided into three key phases: the "Newbie Village" during the 924 bull market, the "Chaos Period" characterized by the rise of "hot stocks," and the "Ultimate King" phase where investors align with large capital [8][29]. - In the "Newbie Village," investors are encouraged to familiarize themselves with the market mechanisms and identify strong stocks, particularly in a bull market where many stocks are rising [11][8]. - The "Chaos Period" involves navigating a market with multiple main lines and identifying leading stocks, known as "hot stocks," which can yield significant returns [16][18]. Group 2: Investment Strategies - During the "Newbie Village," a hypothetical investment of 50,000 yuan in Tianfeng Securities could grow to 103,500 yuan within a short period, demonstrating the potential for quick gains in a rising market [13]. - In the "Chaos Period," investors can achieve substantial returns by identifying and investing in stocks like Shuangcheng Pharmaceutical and Risheng Dongfang, which saw significant price increases due to market narratives and trends [19][20]. - The article emphasizes the importance of understanding market narratives and the emotional dynamics of trading, as these factors can drive stock prices significantly [24]. Group 3: Role of Large Capital - The "Ultimate King" phase highlights the dominance of large capital in the market, with institutional investors and state-owned funds playing a crucial role in stabilizing and driving market trends [30][31]. - Large capital is increasingly focused on technology stocks, which have shown substantial growth potential, contrasting with traditional sectors that have limited growth prospects [34][38]. - The article notes that successful investments in the current market environment require aligning with large capital and understanding the underlying fundamentals of technology-driven companies [39][42].

Core Insights - The article presents a metaphorical guide for stock trading in the A-share market, likening it to a game where players progress from novice to expert levels, with the potential for significant financial gains [1][3]. Group 1: Market Phases - The journey of small capital investment in the A-share market is divided into three key phases: the novice phase, the chaos phase, and the ultimate king phase [3][9]. - In the novice phase, the focus is on understanding the A-share market mechanisms and acquiring initial resources [9]. - The chaos phase involves navigating through various market trends and identifying leading stocks, particularly "妖股" (mythical stocks) [14][23]. - The ultimate king phase emphasizes aligning with large capital players and adopting a following strategy to maximize returns [26][27]. Group 2: Investment Strategies - During the novice phase, a hypothetical investment of 50,000 yuan in Tianfeng Securities could yield a return of 10.35 million yuan within a short period [11][12]. - In the chaos phase, stocks like 双成药业 (Shuangcheng Pharmaceutical) and 日出东方 (Rising East) exemplify the potential for rapid gains through strategic investments based on market narratives and trends [15][17]. - The ultimate king phase highlights the importance of large institutional investors, such as the "国家队" (national team), which have significant influence over market pricing and trends [27][28]. Group 3: Market Dynamics - The article discusses the influx of capital into the A-share market, with a notable increase in trading volume from 500 billion to over 3 trillion yuan during peak periods [5][6]. - It also notes the shift in market dynamics, where large institutional investors have gained more control, leading to a more stable market environment characterized by slow growth and structural trends [31][32]. - The performance of stocks in the technology sector, such as 寒武纪 (Cambricon), is highlighted as a key driver of market growth, contrasting with traditional sectors like banking and oil [34][36]. Group 4: Risks and Challenges - The article emphasizes the inherent risks in the "妖股" trading strategy, where the rapid rise in stock prices can lead to equally swift declines if market narratives fail [23]. - It also points out that while small investors make up a significant portion of the market, they face greater challenges in achieving consistent profits compared to larger institutional players [43].

Group 1 - The core point of the article is that *ST Shuangcheng (SZ 002693) announced the convening of its 22nd meeting of the fifth board of directors on September 19, 2025, to discuss the granting of restricted stocks and stock options under the 2025 incentive plan [1] - For the first half of 2025, *ST Shuangcheng's revenue composition was 89.3% from industrial operations and 10.7% from services [1] - As of the time of reporting, *ST Shuangcheng had a market capitalization of 3.1 billion yuan [1]

重要内容提示： 海南双成药业股份有限公司（以下简称"公司"）2025 年限制性股票与股票 期权激励计划（以下简称"本激励计划"）规定的限制性股票与股票期权授予条 件已经成就，根据公司 2025 年第二次临时股东会授权，公司于 2025 年 9 月 19 日召开了第五届董事会第二十二次会议，审议通过了《关于向 2025 年限制性股 票与股票期权激励计划激励对象授予限制性股票与股票期权的议案》，确定限制 性股票和股票期权的授予日为 2025 年 9 月 19 日，向符合授予条件的 18 名激励 对象授予 1,200 万股限制性股票,向符合授予条件的 131 名激励对象授予 800 万 份股票期权。现将有关事项说明如下： 一、本激励计划简述及已履行的相关审议程序 证券代码：002693 证券简称：*ST双成 公告编号：2025-064 海南双成药业股份有限公司 关于向 2025 年限制性股票与股票期权激励计划 激励对象授予限制性股票与股票期权的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 （一）本激励计划简述 1、授予限制性股票/股票期权的股票来源 本激励计 ...

海南双成药业股份有限公司 | 序号 | 姓名 | 职务 | 序号 | 姓名 | 职务 | | --- | --- | --- | --- | --- | --- | | 11 | 王*雨 | 核心技术（业务）骨干 | 81 | 符* | 核心技术（业务）骨干 | | 12 | 李* | 核心技术（业务）骨干 | 82 | 吴*文 | 核心技术（业务）骨干 | | 13 | 杨* | 核心技术（业务）骨干 | 83 | 王*岩 | 核心技术（业务）骨干 | | 14 | 韩*若 | 核心技术（业务）骨干 | 84 | 许*鸿 | 核心技术（业务）骨干 | | 15 | 莫*鹏 | 核心技术（业务）骨干 | 85 | 王*伟 | 核心技术（业务）骨干 | | 16 | 苏*寿 | 核心技术（业务）骨干 | 86 | 林*就 | 核心技术（业务）骨干 | | 17 | 朱*彦 | 核心技术（业务）骨干 | 87 | 符*飞 | 核心技术（业务）骨干 | | 18 | 吴*德 | 核心技术（业务）骨干 | 88 | 洪*漫 | 核心技术（业务）骨干 | | 19 | 王*燕 | 核心技术（业务）骨干 | 89 | 王 ...